- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Prophylactic Pacemaker Use After TAVR Shows Low Pacing Burden: JACC

A recent study published in the recent issue of JACC: Clinical Electrophysiology journal found low pacing burden following transcatheter aortic valve replacement (TAVR) in patients with prophylactic permanent pacemaker implantation (PPI).
The PROMOTE trial enrolled 2,110 patients without prior pacemakers undergoing TAVR. This research examined whether preemptively implanting pacemakers in patients with new conduction abnormalities could reduce risk or improve outcomes. Prophylactic PPI was triggered by defined electrocardiogram (ECG) criteria, like persistent QRS widening beyond 150 milliseconds or PR intervals exceeding 240 milliseconds, along with progressive conduction changes.
Out of 329 patients who eventually received a pacemaker post-TAVR, 80 patients (24.3%) fell into the prophylactic category. Also, 90% of these cases were driven by the emergence of new, persistent left bundle branch block coupled with the threshold ECG abnormalities.
When this study compared outcomes at 30 days, both prophylactic and non-prophylactic PPI patients had similar clinical results. Mortality, rehospitalization, and adverse event rates did not differ significantly between the two groups. However, those receiving prophylactic PPI demonstrated a median ventricular pacing rate of just 2%, compared with 73% among those implanted for non-prophylactic reasons. Furthermore, 42.6% of prophylactic recipients required virtually no pacing support (<1% pacing), while only 14.5% in the non-prophylactic group reached this threshold.
An additional observation centered on patients undergoing electrophysiological studies (EPS). Even when a prolonged His–ventricle interval (≥70 ms) was confirmed before prophylactic implantation, pacing burdens at follow-up remained minimal and comparable to patients who had not undergone EPS. This suggested that EPS guidance did not significantly influence pacemaker dependency outcomes.
These findings suggest that nearly one in four post-TAVR pacemaker recipients undergo implantation based on prophylactic criteria rather than symptomatic or high-risk events. Yet, most of these patients exhibit minimal reliance on the device afterward.
Overall, this study highlighted the need to carefully reconsider the systematic use of prophylactic pacemaker implantation after TAVR. Although pacing prevents potential late conduction events, the majority of prophylactic cases show very low device dependency at follow-up, raising concerns about over-implantation. The implications are far-reaching as TAVR becomes more widely adopted in lower-risk populations.
Source:
Fischer, Q., Nombela-Franco, L., Muntané-Carol, G., Veiga, G., Regueiro, A., Nazif, T., Serra, V., Asmarats, L., Ribeiro, H. B., Latib, A., Poulin, A., Cheema, A. N., Tirado-Conte, G., Gomez-Hospital, J. A., Gil Ongay, A., Gabani, R., Arzamendi, D., Brener, M., Calabuig, A., … Rodés-Cabau, J. (2025). Prophylactic permanent pacemaker implantation after transcatheter aortic valve replacement. JACC. Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2025.07.028
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

